

Imaging Findings of Common Benign Renal Tumors in the Era of Small Renal Masses: Differential Diagnosis from Small Renal Cell Carcinoma – Current Status and Future Perspectives

Sungmin Woo, MD¹, Jeong Yeon Cho, MD^{1, 2}

¹Department of Radiology, Seoul National University College of Medicine, Seoul 110-744, Korea; ²Institute of Radiation Medicine and Kidney Research Institute, Seoul National University Medical Research Center, Seoul 110-744, Korea

The prevalence of small renal masses (SRM) has risen, paralleling the increased usage of cross-sectional imaging. A large proportion of these SRMs are not malignant, and do not require invasive treatment such as nephrectomy. Therefore, differentiation between early renal cell carcinoma (RCC) and benign SRM is critical to achieve proper management. This article reviews the radiological features of benign SRMs, with focus on two of the most common benign entities, angiomyolipoma and oncocytoma, in terms of their common imaging findings and differential features from RCC. Furthermore, the role of percutaneous biopsy is discussed as imaging is yet imperfect, therefore necessitating biopsy in certain circumstances to confirm the benignity of SRMs.

Index terms: *Small renal mass; Angiomyolipoma; Oncocytoma; Renal cell carcinoma*

INTRODUCTION

The increased detection of small renal tumors has paralleled the increased use of cross-sectional imaging (1). The term small renal mass (SRM) has been used to refer to these tumors, usually defined as an enhancing tumor less than 4 cm in diameter (2). This has resulted in a 2% annual increase in the incidence of renal cell carcinoma (RCC) over the past two decades with a migration to lower stages due to smaller size (2-4). Furthermore, it is not only RCC that have risen in incidence. Incidental SRMs represent both malignant and benign tumors (5). Especially, at smaller SRM sizes, the proportion of benign SRM is higher. For

instance, in a report by Frank et al. (6), it was found that 30% of tumors less than 2 cm in diameter were benign, whereas 20% of those with a diameter greater than 4 cm were benign. In a recent study of a series of 2675 tumors, an increase of 16% in the odds of cancer was equated with each centimeter increase in the size of the mass (7). As a large proportion of SRMs are not malignant, they do not require invasive treatment such as nephrectomy, and follow-up imaging or treatment in the case of symptomatic presentations (i.e., renal artery embolization for bleeding from angiomyolipoma [AML]) may suffice (8). Therefore, differentiation between early RCC and benign SRM has become critical to achieve proper management. As there are a lack of symptoms and clinical characteristics to indicate RCC in SRMs, differential diagnosis is highly dependent on imaging characteristics.

In this review, we describe the radiological features of benign SRMs based on well-known findings in the literature and with incorporation of findings from recent reports. We especially focused on two of the most common benign entities, AML and oncocytoma, in terms of their common imaging findings and differential features from RCC as

Received June 24, 2014; accepted after revision October 28, 2014.

Corresponding author: Jeong Yeon Cho, MD, Department of Radiology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea.

• Tel: (822) 2072-3074 • Fax: (822) 743-6385

• E-mail: radjycho@snu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

they are the most commonly encountered SRMs that could be mistaken as RCC. Detailed description of the imaging findings of less common types of benign SRMs and the radiologic differentiation between subtypes of RCC are beyond the scope of this review. Finally, we introduce the role that percutaneous biopsy may play in the era of SRMs.

Imaging Findings of Common Benign Small Renal Masses

Angiomyolipoma

Angiomyolipoma is one of the most common benign solid renal neoplasms (1). AML is composed of blood vessels, smooth muscle, and adipose tissue (9). It occurs most often in the 4–6th decades, with preponderance in women (10). Radiologically, AML can be categorized into the more classic AML and AML with minimal fat (11). Diagnosing the more classic AML is not difficult, as it presents with gross fat, which is the pathologic hallmark of AML. Owing to this abundant fat component, AMLs show marked hyperechogenicity (usually as echogenic as the renal sinus fat) on ultrasound (US) with reference to the renal parenchyma (12, 13), and demonstrate areas of unenhanced attenuation measuring < -10 Hounsfield units (HU) on computed tomography (CT) (14). In addition, this fat content can be detected by using frequency selective fat suppression and chemical shift fat suppression (15, 16) on magnetic resonance imaging (MRI). In cases of small classic AML, the typical radiologic findings of US, CT, and MRI are all applicable. Yet, as the AML itself and the fat content is small, acquisition of thin sections (i.e., 1.5–3 mm) and measuring the attenuation with small regions of interest or even pixel values might be necessary to identify the fat content while avoiding partial volume averaging artifacts (14, 17, 18).

However, it may be difficult to differentiate AML with minimal fat from RCC (19) as they both contain too little fat to be directly detected on an unenhanced CT. This type of AML is typically reported to be small with an average diameter of 3 cm (19–21). As a result, these AMLs are quite often misdiagnosed as RCC and are inadvertently removed surgically (1). Generally, AML with minimal fat is pathologically diagnosed as an AML that contains no more than 25% fat cells as visualized using high power field microscopy (12). Yet, despite the poor lipid content, many investigators have tried to find methods to identify AML with minimal fat as well as radiologically distinguish it from

RCC and have reported promising results (Table 1).

US Findings of AML with Minimal Fat

Traditionally, a hyperechoic renal mass on US without features of a hypoechoic rim or intratumoral cysts is considered typical for AML when compared with RCC (12). However, when it comes to small AML with minimal fat, there has been some controversy over the echogenicity of AMLs. Some have reported that they are homogeneously isoechoic (20, 21), whereas others found that they are hyperechoic (19) or only slightly hyperechoic (22). Most of these studies comparing the echogenicity of RCC and AML with minimal fat have been done on a subjective basis and are not dedicated studies of SRMs. On the other hand, Lee et al. (23) reported that measuring the relative echogenicity of the lesion at a picture archiving and communication system monitor with the renal cortex and sinus fat referenced as 0 and 100%, respectively, was useful in differentiating small AMLs from RCCs. While small AML with minimal fat (88%) demonstrated lesser relative echogenicity than classic AML (106.3%), it showed greater relative echogenicity compared with all subtypes (44.1%) of RCC (Fig. 1). Although, further validation may be needed, in our experience, we believe that comparing the relative echogenicity with that of sinus fat can be helpful in clinical practice.

CT Findings of AML with Minimal Fat

CT has been more meticulously studied with regard to small AML with minimal fat. One of the most representative findings of AML with minimal fat on CT is the extent of hyperattenuation compared with the renal parenchyma. It was found to be significantly more common in these AMLs (53%) than in RCCs (13%) (24). This finding has also been confirmed upon quantitative analysis with thresholds of > 38.5 HU and > 37 HU to differentiate small AML with minimal fat from RCC and non-clear cell type RCC, respectively, resulting insensitivities and specificities up to 91.7% and 76.4%, respectively (Fig. 2) (25–27). A different approach that has been thoroughly examined is attenuation measurement using histogram analysis on unenhanced CT. Although earlier studies reported promising results with a high specificity (100%) and positive predictive value (100%) (28), further research by different investigators led to the realization that pixel histogram analysis cannot reliably differentiate between AML with minimal fat and RCC, or at least between AML with minimal fat and clear cell RCC (29, 30).

Table 1. Imaging Findings of Small Angiomyolipoma with Minimal Fat

Author (Reference)	Imaging Finding	Modality	Comparison (Number/Mean Size [cm])	Sensitivity (%)	Specificity (%)
Hyperechogenicity on US					
Lee et al. (23)	Relative echogenicity > 56.8%	US	AMLmf (15/2.7) RCC (36/2.2)	80	64
Hyperattenuation on precontrast CT					
Kim et al. (24)	High attenuation relative to adjacent renal parenchyma on unenhanced scan	CT	AMLmf (19/2.8) RCC (62/3.1)	53	87
Woo et al. (25)	Precontrast attenuation > 37 HU	CT	AMLmf (24/2.0) NCCRCC (55/2.2)	92	76
Yang et al. (26)	Precontrast attenuation > 38.5 HU	CT	AMLmf (33/2.8) RCC (102/3.7)	84	82
Kim et al. (27)	High attenuation on unenhanced scan	CT	AMLmf (48/NA) RCC (359/NA)	60	88
Low T2-weighted SI on MRI					
Choi et al. (31)	T2 SI ratio (tumor/spleen) < 92.5%	MRI	AMLmf (10/NA) RCC (57/NA)	90	90
Sasiwimonphan et al. (32)	T2 SI ratio (tumor/cortex) < 90%	MRI	AMLmf (10/2.1) RCC (71/2.4)	100	58
Chemical shift MRI					
Sasiwimonphan et al. (32)	SI index > 20%	MRI	AMLmf (10/2.1) RCC (71/2.4)	33	89
Kim et al. (35)	SI index > 25% Tumor-to-spleen ratio < -32%	MRI	AMLmf (26/2.1) Non-AMLmf (29/2.2)	96 88	93 97
Shape of renal mass on cross-sectional imaging					
Woo et al. (25)	LSR > 1.29	CT	AMLmf (24/2.0) NCCRCC (55/2.2)	79	84
Kim et al. (27)	LSR > 1.13	CT	AMLmf (48/NA*) RCC (359/NA*)	94	64
Verma et al. (38)	Angular interface	MRI	AML[mf] (17[3]/NA) RCC (97/3.3)	76 [100]	100
Kim et al. (39)	Ice-cream cone sign	CT	AMLmf (18/1.6) RCC (135/2.0)	78	84

Note.— *Mean size of all renal masses (48 angiomyolipomas with minimal fat and 359 RCCs) = 2.4 cm. AML = angiomyolipoma, AMLmf = angiomyolipoma with minimal fat, CT = computed tomography, HU = Hounsfield unit, LSR = long-to-short axis ratio, MRI = magnetic resonance imaging, NA = none available, NCCRCC = non-clear cell renal cell carcinoma, RCC = renal cell carcinoma, SI = signal intensity, US = ultrasonography

MRI Findings of AML with Minimal Fat

MRI is often a problem solving modality in equivocal cases. The most basic MRI finding of small AML with minimal fat with regard to differentiation from RCC is low T2-weighted imaging (T2WI) signal intensity (SI). The characteristic low T2WI SI is not only well appreciated on a qualitative basis but has also been quantitatively assessed in terms of the SI ratio of the renal mass to that of the background kidney (31, 32). Choi et al. (31) have used a criteria of T2WI SI ratio < 92.5% for predicting

small AML with minimal fat and reported a high sensitivity and specificity of 90% and 90.2%, respectively. More recently, it has been suggested that fat-suppressed T2WI may be more useful than T2WI without fat saturation when differentiating AML with minimal fat from other entities (33). Chemical shift MRI, or in other words, in- and opposed-phased MRI, is also recognized as effective in differentiation of SRMs, especially in diagnosing AML with minimal fat. In general, the presence of the Indian ink artifact at the interval between the renal mass and kidney




Fig. 1. Comparison of relative echogenicity between small renal cell carcinoma (RCC) and angiomyolipoma (AML) with minimal fat.

A. Mass (arrow) in right kidney lower pole in 43-year-old woman shows high echogenicity but less than that of sinus fat. Relative echogenicity ($[\text{echogenicity of mass} - \text{echogenicity of renal cortex}] / [\text{echogenicity of sinus fat} - \text{echogenicity of renal cortex}]$) was calculated as 0.63. Upon surgery, mass was confirmed as clear cell RCC. **B.** Mass (arrow) in left kidney interpoler in 38-year-old woman shows high echogenicity, even higher than that of sinus fat. Relative echogenicity was measured as 2.10. Mass was confirmed as AML with minimal fat at surgery.

or SI loss at opposed phase images within a renal mass can suggest the diagnosis of AML (16). Furthermore, chemical shift MRI has been reported to be able to detect fat even in cases of AML (with minimal fat) where CT failed to detect fatty tissue (34). Upon quantitative analysis, SI indices (the relative drop of SI from in- to opposed-phase) of 20–25% resulted in specificities of 90–93% in diagnosing small AML with minimal fat from non-AMLs (32, 35). Although MRI is often helpful in indeterminate cases on CT, some pitfalls should be noted when using certain methods such as the two above. In general (not limited to the SRMs), papillary RCCs also appear as T2WI low SI renal masses, and clear cell RCCs sometimes demonstrate loss of SI in the opposed phase due to intracytoplasmic fat, hindering diagnostic accuracy in determining AML with minimal fat (36, 37). Therefore, when interpreting MR examinations for characterization of SRMs, one should not rely on a single criterion, but rather comprehensively incorporate all given features, such as low T2WI SI, loss of SI at opposed phase images, and enhancement pattern.

Apart from the abundant literature using CT and MRI in diagnosing small AML with minimal fat, a common cross-sectional imaging feature may also aid in diagnostic confidence. Small AMLs with minimal fat are usually less rounded in shape compared with small RCC (Fig. 3). This is substantiated by several reports in the literature, which described small AML with minimal fat as having an angular interface with the renal parenchyma, demonstrating greater long-to-short axis ratio compared with RCC (> 1.13) or non-clear cell RCC (> 1.29). They were even characterized to resemble the morphology of an ice-cream cone (25, 27,

38, 39). All these descriptions fundamentally imply that small AML with minimal fat are softer than RCC due to their composition of adipose tissue (minimal in the case of AML with minimal fat), smooth muscle, and blood vessels in AML unlike the compact cellular growth pattern in RCC (9, 40, 41).

Several emerging technologies have been explored recently. Tan et al. (42) found that sonoelastography was able to differentiate small AML with minimal fat from RCC, with high interobserver concordance and accuracy. There also have been recent efforts using diffusion-weighted MR imaging (DWI) to diagnose AML with minimal fat (43–45). Yet, the literature is still scarce, controversial, and do not specifically handle SRMs, warranting validation before clinical utilization.

Oncocytoma

Oncocytoma is the second most common benign renal cell neoplasm constituting approximately 5% of renal epithelial neoplasms based on surgical series (9). Oncocytoma is thought to originate from or to histologically differentiate towards the type A intercalated cells of the cortical collecting duct (46, 47). The incidence of oncocytoma peaks in the seventh decade, with a higher prevalence in men. Histopathologically, oncocytoma is organized with acini and nests of large polygonal cells and contains eosinophilic cytoplasm rich in mitochondria (9). A recent study of pathologically proven oncocytomas demonstrated that the mean growth rate of oncocytomas was 2.9 mm/year over 36 months, which is equivalent to the rate previously reported for RCCs and other small renal masses (48). Therefore,




Fig. 2. 24-year-old man with small angiomyolipoma with minimal fat in right kidney demonstrating typical CT and MR findings. **A.** Axial precontrast CT scan reveals oval shaped 1.8-cm sized hyperdense mass (arrow) in right kidney upper pole. At region of interest measurement, attenuation of mass was 51 Hounsfield units (HU) while renal parenchyma was measured as 39 HU. **B, C.** Axial corticomedullary phase (**B**) and early excretory phase (**C**) CT scan shows that mass (arrow) is less enhanced compared with renal parenchyma. **D.** Renal mass (arrow) demonstrates low signal intensity (SI) compared with renal parenchyma on coronal T2-weighted image. **E, F.** On coronal chemical shift MR imaging, suspicious focus (arrow) of SI drop from in phase (**E**) to opposed phase (**F**) is noted. **G-I.** Coronal contrast-enhanced MRI shows that mass (arrow) is less enhanced than background renal parenchyma.




Fig. 3. 53-year-old man with small angiomyolipoma with minimal fat showing ice-cream cone appearance.
A. Small enhancing renal mass in left kidney anterior aspect is depicted on axial corticomedullary phase CT. Mass is composed of two portions, exophytic portion (arrow) with rounded appearance and intraparenchymal component (arrowhead) with wedge or triangular shape, resembling ice-cream cone. **B.** At sagittal early excretory phase CT, ice-cream cone appearance constituted with exophytic (arrow) and endophytic portions (arrowhead) of renal mass is again well demonstrated. Mass was diagnosed as angiomyolipoma with minimal fat at surgery.

surveillance may not be able to discriminate a small oncocytoma from a small RCC, and rather the radiologist, if possible, should suggest the possibility of oncocytoma when suspected on imaging. Imaging findings reported for small renal oncocytoma are summarized in Table 2.

US Findings of Oncocytoma

On US, small sized oncocytomas usually appear as homogeneous renal masses that are isoechoic with the echogenicity of the renal parenchyma with well-demarcated margins (49). Yet, small RCCs may also show similar characteristics in about 5–6% of cases (50). The spoke wheel or stellate scar appearance on US, which is a well-known characteristic finding, is usually difficult to see in small oncocytomas. For instance, Goiney et al. (49) only found the central scar present in an oncocytoma sized 12 cm. This can be explained by the fact that the oncocytoma needs to enlarge and outstrip its blood supply leading to infarction hemorrhage and necrosis before organizing and healing to render the central scar. A spoke-wheel pattern of feeding arteries on angiography, though characteristic of oncocytoma, is again mostly seen in oncocytomas of larger sizes, and cannot be accurately used to diagnosis oncocytomas in the setting of SRMs (51).

CT Findings of Oncocytoma

On CT, small oncocytomas typically appear as solitary,

well-demarcated, homogeneously enhancing renal cortical tumors. Hemorrhage, calcification, necrosis, and central stellate scars are uncommon in oncocytomas in the setting of SRMs (51-54). Although these imaging findings of small oncocytomas overlap with RCC and may discourage efforts to differentiate between the two, fortunately, we have recognized that a phenomenon called “segmental enhancement inversion” could be helpful in such a situation. Segmental enhancement inversion (SEI) was defined as the following by Kim et al. (55): on contrast-enhanced CT, renal mass demonstrates two distinct areas of differing degrees of enhancement in the corticomedullary phase, in which the degree of enhancement is inverted in the nephrographic phase (Fig. 4). In the first study introducing this finding of SEI, it was found to be a characteristic finding of small oncocytoma with 8 of 10 (80%) oncocytomas smaller than or equal to 4 cm showing SEI. In a subsequent study that analyzed the prevalence of SEI according to the size of oncocytomas, it was found that oncocytomas in the size range of 1.5–2.9 cm most commonly showed SEI (56). A possible explanation is that an extremely small size (< 1.5 cm) makes it difficult to segment the oncocytoma into more and less enhancing components, and that the increasing proportion of tumors with pathological features such as the stellate scar coincide with the decreased prevalence of SEI in oncocytomas with larger size (> 2.5 cm). Furthermore, SEI was found to be

significantly more common in small oncocytoma (63%) than in small chromphobe RCC (7.3%), which may be expected to manifest with similar imaging findings given their common histopathological backgrounds (57). Ever

since these preliminary results were reported, there has been some debate over the utility of this imaging finding (58, 59). For instance, McGahan et al. (58) found that only 1 out of 16 (6.3%) renal oncocytomas showed SEI. Possible

Table 2. Imaging Findings of Small Oncocytoma

Author (Reference)	Imaging Finding	Modality	Comparison (Number/Mean Size [cm])	Sensitivity (%)	Specificity (%)
US					
Goiney et al. (49)	Homogeneous, isoechoic, well demarcated	US	Oncocytoma (9/NA*) No comparison	NA	NA
Quantitative enhancement pattern					
Alshumrani et al. (61)	Nephrographic enhancement > 32 HU	CT	Oncocytoma (9/NA [†]) Papillary RCC (7/NA [†])	100	100
Gakis et al. (62)	Corticomedullary phase tumor to renal cortex attenuation difference < 25 HU	CT	Oncocytoma (10/2.8) Clear cell RCC (10/2.5)	NA	NA
Bird et al. (63)	Arterial phase enhancement > 500% Washout at delayed phase > 50%	CT	Oncocytoma (12/NA [‡]) RCC (67/NA [‡])	NA NA	100 100
Segmental enhancement inversion					
Kim et al. (55)	Segmental enhancement inversion	CT	Oncocytoma (10/2.3) RCC (88/2.6)	80	99
Woo et al. (57)	Segmental enhancement inversion	CT	Oncocytoma (27/2.5) Chromophobe RCC (55/2.4)	63	93

Note.— *All 9 oncocytomas sized < 5.5 cm, [†]Mean size of all renal masses (9 oncocytomas and 7 papillary RCCs) = 2.5 cm, [‡]Mean size of all renal masses (12 oncocytomas and 67 RCCs) = 2.6 cm. CT = computed tomography, HU = Hounsfield unit, NA = none available, RCC = renal cell carcinoma, US = ultrasonography




Fig. 4. 44-year-old woman with small oncocytoma demonstrating segmental enhancement inversion.

A. On coronal corticomedullary phase CT, renal mass at right kidney upper pole can be segmented into two areas. Crescent-shaped area at right aspect (white arrow) is more enhanced compared with relatively round shaped portion (black arrow) with heterogeneous enhancement at left aspect. Note adjacent medulla (arrowhead) at lateral aspect of renal mass which is less enhanced compared with well enhancing portion of renal mass. **B.** On coronal early excretory phase CT, enhancement degree of aforementioned two segments of renal mass is reversed. While previously more enhanced right crescent-shaped area (white arrow) is now less enhanced, round portion at left aspect (black arrow) shows marked enhancement, consistent with segmental enhancement inversion. Note that corticomedullary phase hypodense area and early excretory phase hyperattenuating area (arrowhead) are not part of mass but adjacent medullary tissue.

explanations for this discrepancy may be differences in the study population (i.e., tumor size), methods and the level of experience in recognizing SEI, as well as differences in the CT protocols (i.e., time delay after contrast injection for the corticomedullary and early excretory phases).

Although the clinical usefulness of SEI may need further verification, it is indeed promising that specificity remains high throughout various reports (87–100%) according to a recent meta-analysis of SEI in diagnosing oncocytoma which has summarized the debate (60).

Recent reports suggest that quantitative analysis of the enhancement pattern of SRMs may assist in identifying oncocytomas. Alshumrani et al. (61) reported that by using triphasic multidetector CT in a cohort of 47 small renal masses, they were able to distinguish oncocytomas from papillary RCCs using a threshold of 32 HU for absolute nephrographic enhancement. Furthermore, Gakis et al. (62) found that the corticomedullary phase was the best phase to differentiate between small oncocytoma and clear cell RCC. In their study, small oncocytomas were more isoattenuating to the normal renal cortex, whereas clear cell RCCs were more hyperenhancing. However, Bird et al. (63) demonstrated that on 4-phase contrast-enhanced CT, oncocytomas showed higher enhancement than clear cell RCCs with arterial phase enhancement greater than 500% and washout values greater than 50%, in which the latter was exclusively seen in oncocytomas. Such discrepancy in quantitative measurements of enhancement degrees are speculated to arise from different CT protocols, and however promising they seem to be, more standardized protocols are needed for direct comparison between studies, and to establish the role of quantitative analysis of the enhancement pattern for diagnosing small renal oncocytoma.

MRI Findings of Oncocytoma

MRI has also been evaluated for its value in diagnosing oncocytoma; however, the literature is sparse with respect to small renal oncocytoma. Rosenkrantz et al. (64) compared an array of MR imaging features between oncocytoma and chromophobe RCC and none of the evaluated features of microscopic fat, hemorrhage, cysts, infiltrative margins, perinephric fat invasion, renal vein invasion, enhancement homogeneity, hypervascularity, central scar, and SEI were significantly different. Rather, both entities appeared as localized well-circumscribed masses, more hypovascular than the renal cortex, with low prevalence of features of

cysts, microscopic lipid, hemorrhage, and hemosiderin. However, other studies suggested that oncocytomas can be identified with high specificity (65, 66). Cornelis et al. (65) reported that SEI of the central area was observed in 74% of oncocytomas and in 12% of RCCs. And when they used a combination of SEI and SI index $< 2\%$ or tumor-to-spleen ratio $> -6\%$, they were able to diagnose oncocytoma with a sensitivity of 36–55% and specificity of 95–97%. This group took their investigations further and investigated whether the use of multiparametric MR, including double-echo chemical shift, dynamic contrast-enhanced T1-weighted and T2-weighted images and apparent diffusion coefficient (ADC) maps with the corresponding SI index, tumor-to-spleen SI ratio, ADC ratio, wash-in and wash-out indices between different phases could be of further value (66). Using these parameters, oncocytomas were distinguished from chromophobe and clear cell RCCs with a specificity of 100% and 94.2%, respectively. More recently, advanced MR techniques such as arterial spin labeling (ASL) and DWI have emerged. Lanzman et al. (67) demonstrated that oncocytomas showed higher levels of mean perfusion on ASL MR imaging when compared with all subtypes of RCC, including the clear cell, papillary, chromophobe, and unclassified types. This is similar to the finding of Bird et al. (63) indicating that the degree of arterial enhancement was greater in oncocytomas compared with clear cell RCC using 4-phase contrast enhanced CT. Regarding DWI, a recent meta-analysis which reviewed the ADC values for different renal lesions, identified that not only could ADC values ($\times 10^{-3} \text{ mm}^2/\text{s}$) help generally discriminate between benign and malignant lesions, but they were also able to help differentiate oncocytomas (2.00 ± 0.08) from RCCs (1.61 ± 0.08) (68). Despite these promising results using MRI, the majority of the investigators did not limit their study population to small renal masses, and one should take caution in applying these results, especially when dealing with small renal oncocytomas (64–68).

Although most oncocytomas are solitary, patients may present with bilateral, multicentric oncocytomas in hereditary syndromes such as renal oncocytosis and Birt-Hogg-Dubé syndrome. Oncocytomas can also manifest as hybrid or collision tumors with chromophobes or even other types of RCC (69, 70). In these cases, differentiation between small oncocytomas and RCCs may become more problematic.

Imaging Findings of Other Benign Renal Tumors

Benign renal tumors other than the common AML and oncocytoma include metanephric adenoma, leiomyoma, reninoma, solitary fibrous tumor, schwannoma, and inflammatory pseudotumors which may mimic RCC, usually the non-clear cell type. In the setting of SRMs, discriminating these tumors from small RCC based on imaging is usually impossible, due to the overlap of radiological findings and the rare incidence, and also because the imaging findings of these rare benign renal tumors have not been well established. The following is a brief orientation of the findings of a few representative benign renal tumors.

Metanephric Adenoma

Metanephric adenoma is a rare benign renal tumor which usually occurs in the fifth to sixth decade and is two times more common in females than in males (9). Metanephric

adenoma presents as a well-demarcated, round, solid mass on imaging studies (71). On US, it appears as an expansile mass with either hypo- or hyperechogenicity (72). On CT, it appears as a hyperdense mass in relation to adjacent renal parenchyma on precontrast images with weak enhancement (73). These imaging findings overlap with malignant renal tumors such as Wilms tumor and hypovascular renal cell carcinoma (Fig. 5). Calcification is found in 20% of cases. On MR, it shows as hypointense SI on T1-weighted images and slightly hyperintense SI on T2-weighted images (74).

Leiomyoma

Renal leiomyoma is a rare benign tumor arising from the smooth muscle (9). It is usually detected in adults as an incidental finding. Renal capsule is the most common site of leiomyoma, but it can also develop from the renal pelvis or cortex, albeit very rarely (75). Renal leiomyoma commonly appears as a well-circumscribed, homogeneous, exophytic hyperattenuating solid mass showing




Fig. 5. 33-year-old woman with small metanephric adenoma.

A. Mass at right kidney upper pole is slightly more hyperdense (arrow) than renal parenchyma at axial precontrast CT. **B, C.** Mass (arrow) is poorly enhancing compared with renal parenchyma at axial corticomedullary phase (**B**) and early excretory phase (**C**). Mass was confirmed as metanephric adenoma upon surgical resection.

homogeneous enhancement on contrast-enhanced CT (76). Heterogeneous features due to hemorrhage and cystic or myxoid degeneration are rare when leiomyomas are small (77). At MRI, leiomyoma typically has homogeneously low SI on T1- and T2-weighted images (Fig. 6) (78).

Juxtaglomerular Cell Tumor

Juxtaglomerular cell (JGC) tumor, also known as reninoma, is an extremely rare, benign renal tumor of myoendocrine cell origin (79). Almost all cases occur in the second and third decades with 2:1 female preponderance. With regard to diagnosing JGC tumor, the clinically setting is of utmost importance. A patient with JGC tumor typically manifests with a triad of poorly controlled hypertension, hypokalemia, and high plasma renin activity (80). At imaging, JGC tumors classically appear as a unilateral, well-marginated, cortical tumor smaller than 3 cm (81). JGC tumors usually appear hypovascular with delayed enhancement on contrast-enhanced CT and MRI despite its profuse vascularity (Fig. 7). This is speculated to be due to renin-induced vasoconstriction (82).

Role of Percutaneous Biopsy in the Era of Small Renal Masses

It is ironic that while there are so many reports demonstrating the high accuracy and efficacy of imaging studies, especially cross-sectional studies such as CT and MRI, the majority of these studies are based on surgical specimens of benign and malignant SRMs. Remzi et al. (83) reported that only 17% of all benign renal masses were correctly diagnosed at preoperative CT, yet 43% of these patients underwent overtreatment, such as radical nephrectomy. In another study, Frank et al. (6) found that this was the case in 65% of 376 benign renal masses. Surgical data have been especially consistent in demonstrating that the smaller the size of a solid renal mass, the higher the probability of it being a benign lesion (6, 84, 85). Among these unnecessarily resected benign renal masses, the most common include AML with minimal fat and oncocytoma, while the more rare entities would be metanephric adenoma, papillary adenoma, and leiomyoma. As these SRMs have historically undergone unnecessary




Fig. 6. 43-year-old woman with small renal leiomyoma.

A. Renal mass (arrow) is located at right kidney capsular area abutting right hemiliver. On axial precontrast CT scan, mass is hyperdense in comparison with renal parenchyma. **B, C.** Axial corticomedullary (**B**) and early excretory phase (**C**) CT reveals that renal mass (arrow) is homogeneously enhanced. Renal mass was diagnosed as leiomyoma after surgery.




Fig. 7. 23-year-old woman with small juxtaglomerular cell tumor and underlying hypertension.

A. Power Doppler ultrasound demonstrates renal mass (arrow) with poor vascularity. **B, C.** Axial corticomedullary (**B**) and nephrographic (**C**) CT shows same mass (arrow) without prominent enhancement in right kidney. At surgery, mass was confirmed as juxtaglomerular cell tumor.

surgery, it could be suggested that biopsy should be done before deciding whether the patient should undergo invasive management (operation) or not in certain circumstances. We do not believe that there is a clear cut indication for performing a biopsy on all small renal masses, nor do we have a set of criteria to choose whom and what tumor will require biopsy. This remains an important clinical question to be solved. Yet it is undisputed that recent advances in the acquisition and interpretation of biopsy specimens from SRMs have had a crucial impact. In general, the

sensitivity and specificity of biopsy (regardless of needle size or whether cytological, histological analysis or both were performed) in renal masses is reported to be 80–92% and 83–100%, respectively (86). When stratified to tumor size, the literature indicates that SRMs, in comparison to larger tumors, may be more difficult to diagnose based on percutaneous biopsy. Rybicki et al. (87) reported a sensitivity and negative predictive value of 84% and 60%, respectively, for renal masses smaller than 4 cm, while these values were 97% and 89%, respectively, for those between

4 and 6 cm in size. This is generally thought to be due to difficulty targeting the mass, especially in renal masses smaller than 1 cm in diameter (88). Although we routinely use an 18-gauge biopsy needle at our institution, recent studies suggest that fine (20-gauge or thinner) needles are sufficient to obtain specimens to make an accurate diagnosis (89, 90). Especially, there has been improvement in cytological techniques, including immunocytochemical staining and cytogenetic studies that have led to more accurate diagnoses. The advanced techniques have improved not only differentiation of benign and malignant renal tumors, but can also be helpful in determination of renal cell carcinoma subtypes and Fuhrman nuclear grades (91-95). One important concern regarding percutaneous biopsy of SRMs is needle track seeding in case the SRM is malignant. However, the paucity of such events in the literature suggests that it is a truly rare phenomenon with an estimated incidence of less than 0.01% of cases (96). In addition, there is no evidence to suggest any relationship between needle size and the risk of track seeding (97). The only deterrent to biopsy would be when the SRM is suspected to be transitional cell carcinoma, as some consider these tumors to have a greater risk of seeding than RCCs (98, 99).

Although radiological imaging has been the primary tool to evaluate SRMs, imaging alone may not be able to obviate surgery for all benign SRMs. We believe that percutaneous biopsy will play a crucial role in determining the optimal management of patients with SRM. Still, consensus on when and how percutaneous biopsy should be performed for SRMs will need to be validated in the future.

CONCLUSION

Small renal masses are being detected more frequently due to the increased use of cross-sectional imaging studies. As a significant portion of these SRMs are benign, it is crucial that the radiologist recognize the imaging features of SRMs so that the patient may undergo appropriate management. Several characteristic imaging features of common benign SRMs, such as AML with minimal fat and oncocytoma, are currently well established in the literature, with many more promising results using conventional or advanced imaging techniques on the way. Small-sized rare benign renal tumors, including metanephric adenoma, leiomyoma, and JGC tumor, cannot be accurately diagnosed or differentiated from small RCC, especially non-clear cell

type RCCs based on radiologic studies alone. However, clues should be obtained from the clinical setting, such as the age, sex, symptom, and location of the tumor, and in certain circumstances, percutaneous biopsy will be required to confirm the benignity of the SRM to obviate unnecessary surgery.

REFERENCES

1. Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. *Radiology* 2008;249:16-31
2. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. *N Engl J Med* 2010;362:624-634
3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. *Nat Rev Urol* 2010;7:245-257
4. Reis LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlander N, Horner MJ, et al. *SEER Cancer Statistics Review, 1975-2007*. Bethesda, MD: National Cancer Institute, 2008
5. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, Ficarra V, Cindolo L, de la Taille A, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. *Cancer* 2007;109:868-874
6. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. *J Urol* 2003;170(6 Pt 1):2217-2220
7. Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. *J Urol* 2009;181:2033-2036
8. Sivalingam S, Nakada SY. Contemporary minimally invasive treatment options for renal angiomyolipomas. *Curr Urol Rep* 2013;14:147-153
9. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. *World Health Organization Classification of Tumors. Pathology and genetics of tumors of the Urinary System and Male Genital Organs*. Lyon: IARC Press, 2004:65-66
10. Tamboli P, Ro JY, Amin MB, Ligato S, Ayala AG. Benign tumors and tumor-like lesions of the adult kidney. Part II: benign mesenchymal and mixed neoplasms, and tumor-like lesions. *Adv Anat Pathol* 2000;7:47-66
11. Lane BR, Aydin H, Danforth TL, Zhou M, Remer EM, Novick AC, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. *J Urol* 2008;180:836-843
12. Siegel CL, Middleton WD, Teefey SA, McClennan BL. Angiomyolipoma and renal cell carcinoma: US differentiation. *Radiology* 1996;198:789-793
13. Jinzaki M, Ohkuma K, Tanimoto A, Mukai M, Hiramatsu K, Murai M, et al. Small solid renal lesions: usefulness of power Doppler US. *Radiology* 1998;209:543-550
14. Bosniak MA, Megibow AJ, Hulnick DH, Horii S, Raghavendra BN. CT diagnosis of renal angiomyolipoma: the importance of detecting small amounts of fat. *AJR Am J Roentgenol* 1988;151:497-501
15. Lemaître L, Claudon M, Dubrulle F, Mazeman E. Imaging of

- angiomyolipomas. *Semin Ultrasound CT MR* 1997;18:100-114
16. Israel GM, Hindman N, Hecht E, Krinsky G. The use of opposed-phase chemical shift MRI in the diagnosis of renal angiomyolipomas. *AJR Am J Roentgenol* 2005;184:1868-1872
 17. Takahashi K, Honda M, Okubo RS, Hyodo H, Takakusaki H, Yokoyama H, et al. CT pixel mapping in the diagnosis of small angiomyolipomas of the kidneys. *J Comput Assist Tomogr* 1993;17:98-101
 18. Kurosaki Y, Tanaka Y, Kuramoto K, Itai Y. Improved CT fat detection in small kidney angiomyolipomas using thin sections and single voxel measurements. *J Comput Assist Tomogr* 1993;17:745-748
 19. Hafron J, Fogarty JD, Hoenig DM, Li M, Berkenblit R, Ghavamian R. Imaging characteristics of minimal fat renal angiomyolipoma with histologic correlations. *Urology* 2005;66:1155-1159
 20. Jinzaki M, Tanimoto A, Narimatsu Y, Ohkuma K, Kurata T, Shinmoto H, et al. Angiomyolipoma: imaging findings in lesions with minimal fat. *Radiology* 1997;205:497-502
 21. Trigaux JP, Pauls C, Van Beers B. Atypical renal hamartomas: ultrasonography, computed tomography, and angiographic findings. *J Clin Ultrasound* 1993;21:41-44
 22. Jinzaki M, Silverman SG, Akita H, Nagashima Y, Mikami S, Oya M. Renal angiomyolipoma: a radiological classification and update on recent developments in diagnosis and management. *Abdom Imaging* 2014;39:588-604
 23. Lee MS, Cho JY, Kim SH. Ultrasonographic differentiation of small angiomyolipoma from renal cell carcinoma by measuring relative echogenicity on PACS. *J Korean Soc Ultrasound Med* 2010;29:105-113
 24. Kim JK, Park SY, Shon JH, Cho KS. Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT. *Radiology* 2004;230:677-684
 25. Woo S, Cho JY, Kim SH, Kim SY. Angiomyolipoma with minimal fat and non-clear cell renal cell carcinoma: differentiation on MDCT using classification and regression tree analysis-based algorithm. *Acta Radiol* 2014;55:1258-1269
 26. Yang CW, Shen SH, Chang YH, Chung HJ, Wang JH, Lin AT, et al. Are there useful CT features to differentiate renal cell carcinoma from lipid-poor renal angiomyolipoma? *AJR Am J Roentgenol* 2013;201:1017-1028
 27. Kim MH, Lee J, Cho G, Cho KS, Kim J, Kim JK. MDCT-based scoring system for differentiating angiomyolipoma with minimal fat from renal cell carcinoma. *Acta Radiol* 2013;54:1201-1209
 28. Simpfendorfer C, Herts BR, Motta-Ramirez GA, Lockwood DS, Zhou M, Leiber M, et al. Angiomyolipoma with minimal fat on MDCT: can counts of negative-attenuation pixels aid diagnosis? *AJR Am J Roentgenol* 2009;192:438-443
 29. Chaudhry HS, Davenport MS, Nieman CM, Ho LM, Neville AM. Histogram analysis of small solid renal masses: differentiating minimal fat angiomyolipoma from renal cell carcinoma. *AJR Am J Roentgenol* 2012;198:377-383
 30. Catalano OA, Samir AE, Sahani DV, Hahn PF. Pixel distribution analysis: can it be used to distinguish clear cell carcinomas from angiomyolipomas with minimal fat? *Radiology* 2008;247:738-746
 31. Choi HJ, Kim JK, Ahn H, Kim CS, Kim MH, Cho KS. Value of T2-weighted MR imaging in differentiating low-fat renal angiomyolipomas from other renal tumors. *Acta Radiol* 2011;52:349-353
 32. Sasiwimonphan K, Takahashi N, Leibovich BC, Carter RE, Atwell TD, Kawashima A. Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. *Radiology* 2012;263:160-168
 33. Chung MS, Choi HJ, Kim MH, Cho KS. Comparison of T2-weighted MRI with and without fat suppression for differentiating renal angiomyolipomas without visible fat from other renal tumors. *AJR Am J Roentgenol* 2014;202:765-771
 34. Kido T, Yamashita Y, Sumi S, Baba Y, Takahashi M, Ootsuka Y, et al. Chemical shift GRE MRI of renal angiomyolipoma. *J Comput Assist Tomogr* 1997;21:268-270
 35. Kim JK, Kim SH, Jang YJ, Ahn H, Kim CS, Park H, et al. Renal angiomyolipoma with minimal fat: differentiation from other neoplasms at double-echo chemical shift FLASH MR imaging. *Radiology* 2006;239:174-180
 36. Hindman N, Ngo L, Genega EM, Melamed J, Wei J, Braza JM, et al. Angiomyolipoma with minimal fat: can it be differentiated from clear cell renal cell carcinoma by using standard MR techniques? *Radiology* 2012;265:468-477
 37. Oliva MR, Glickman JN, Zou KH, Teo SY, Mortelé KJ, Rocha MS, et al. Renal cell carcinoma: t1 and t2 signal intensity characteristics of papillary and clear cell types correlated with pathology. *AJR Am J Roentgenol* 2009;192:1524-1530
 38. Verma SK, Mitchell DG, Yang R, Roth CG, O'Kane P, Verma M, et al. Exophytic renal masses: angular interface with renal parenchyma for distinguishing benign from malignant lesions at MR imaging. *Radiology* 2010;255:501-507
 39. Kim KH, Yun BH, Jung SI, Hwang IS, Hwang EC, Kang TW, et al. Usefulness of the ice-cream cone pattern in computed tomography for prediction of angiomyolipoma in patients with a small renal mass. *Korean J Urol* 2013;54:504-509
 40. van den Berg E, Dijkhuizen T, Oosterhuis JW, Geurts van Kessel A, de Jong B, Störkel S. Cytogenetic classification of renal cell cancer. *Cancer Genet Cytogenet* 1997;95:103-107
 41. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. *Am J Surg Pathol* 1997;21:621-635
 42. Tan S, Özcan MF, Tezcan F, Balci S, Karaoğlanoğlu M, Huddam B, et al. Real-time elastography for distinguishing angiomyolipoma from renal cell carcinoma: preliminary observations. *AJR Am J Roentgenol* 2013;200:W369-W375
 43. Tanaka H, Yoshida S, Fujii Y, Ishii C, Tanaka H, Koga F, et al. Diffusion-weighted magnetic resonance imaging in the differentiation of angiomyolipoma with minimal fat from clear cell renal cell carcinoma. *Int J Urol* 2011;18:727-730
 44. Sasamori H, Saiki M, Suyama J, Ohgiya Y, Hirose M, Gokan T.

- Utility of apparent diffusion coefficients in the evaluation of solid renal tumors at 3T. *Magn Reson Med Sci* 2014;13:89-95
45. Agnello F, Roy C, Bazille G, Galia M, Midiri M, Charles T, et al. Small solid renal masses: characterization by diffusion-weighted MRI at 3 T. *Clin Radiol* 2013;68:e301-e308
 46. Störkel S, Pannen B, Thoenes W, Steart PV, Wagner S, Drenckhahn D. Intercalated cells as a probable source for the development of renal oncocytoma. *Virchows Arch B Cell Pathol Incl Mol Pathol* 1988;56:185-189
 47. Geramizadeh B, Ravanshad M, Rahsaz M. Useful markers for differential diagnosis of oncocytoma, chromophobe renal cell carcinoma and conventional renal cell carcinoma. *Indian J Pathol Microbiol* 2008;51:167-171
 48. Kurup AN, Thompson RH, Leibovich BC, Harmsen WS, Sebo TJ, Callstrom MR, et al. Renal oncocytoma growth rates before intervention. *BJU Int* 2012;110:1444-1448
 49. Goiney RC, Goldenberg L, Cooperberg PL, Charboneau JW, Rosenfield AT, Russin LD, et al. Renal oncocytoma: sonographic analysis of 14 cases. *AJR Am J Roentgenol* 1984;143:1001-1004
 50. Charboneau JW, Hattery RR, Ernst EC 3rd, James EM, Williamson B Jr, Hartman GW. Spectrum of sonographic findings in 125 renal masses other than benign simple cyst. *AJR Am J Roentgenol* 1983;140:87-94
 51. Quinn MJ, Hartman DS, Friedman AC, Sherman JL, Lautin EM, Pyatt RS, et al. Renal oncocytoma: new observations. *Radiology* 1984;153:49-53
 52. Jasinski RW, Amendola MA, Glazer GM, Bree RL, Gikas PW. Computed tomography of renal oncocytomas. *Comput Radiol* 1985;9:307-314
 53. Ambos MA, Bosniak MA, Valensi QJ, Madayag MA, Lefleur RS. Angiographic patterns in renal oncocytomas. *Radiology* 1978;129:615-622
 54. Davidson AJ, Hayes WS, Hartman DS, McCarthy WF, Davis CJ Jr. Renal oncocytoma and carcinoma: failure of differentiation with CT. *Radiology* 1993;186:693-696
 55. Kim JI, Cho JY, Moon KC, Lee HJ, Kim SH. Segmental enhancement inversion at biphasic multidetector CT: characteristic finding of small renal oncocytoma. *Radiology* 2009;252:441-448
 56. Woo S, Cho JY, Kim SH, Kim SY, Lee HJ, Hwang SI, et al. Segmental enhancement inversion of small renal oncocytoma: differences in prevalence according to tumor size. *AJR Am J Roentgenol* 2013;200:1054-1059
 57. Woo S, Cho JY, Kim SH, Kim SY. Comparison of segmental enhancement inversion on biphasic MDCT between small renal oncocytomas and chromophobe renal cell carcinomas. *AJR Am J Roentgenol* 2013;201:598-604
 58. McGahan JP, Lamba R, Fisher J, Starshak P, Ramsamoj R, Fitzgerald E, et al. Is segmental enhancement inversion on enhanced biphasic MDCT a reliable sign for the noninvasive diagnosis of renal oncocytomas? *AJR Am J Roentgenol* 2011;197:W674-W679
 59. O'Malley ME, Tran P, Hanbidge A, Rogalla P. Small renal oncocytomas: is segmental enhancement inversion a characteristic finding at biphasic MDCT? *AJR Am J Roentgenol* 2012;199:1312-1315
 60. Schieda N, McInnes MD, Cao L. Diagnostic accuracy of segmental enhancement inversion for diagnosis of renal oncocytoma at biphasic contrast enhanced CT: systematic review. *Eur Radiol* 2014;24:1421-1429
 61. Alshumrani G, O'Malley M, Ghai S, Metser U, Kachura J, Finelli A, et al. Small (< or = 4 cm) cortical renal tumors: characterization with multidetector CT. *Abdom Imaging* 2010;35:488-493
 62. Gakis G, Kramer U, Schilling D, Kruck S, Stenzl A, Schlemmer HP. Small renal oncocytomas: differentiation with multiphase CT. *Eur J Radiol* 2011;80:274-278
 63. Bird VG, Kanagarajah P, Morillo G, Caruso DJ, Ayyathurai R, Leveillee R, et al. Differentiation of oncocytoma and renal cell carcinoma in small renal masses (<4 cm): the role of 4-phase computerized tomography. *World J Urol* 2011;29:787-792
 64. Rosenkrantz AB, Hindman N, Fitzgerald EF, Niver BE, Melamed J, Babb JS. MRI features of renal oncocytoma and chromophobe renal cell carcinoma. *AJR Am J Roentgenol* 2010;195:W421-W427
 65. Cornelis F, Lasserre AS, Tourdias T, Deminière C, Ferrière JM, Le Bras Y, et al. Combined late gadolinium-enhanced and double-echo chemical-shift MRI help to differentiate renal oncocytomas with high central T2 signal intensity from renal cell carcinomas. *AJR Am J Roentgenol* 2013;200:830-838
 66. Cornelis F, Tricaud E, Lasserre AS, Petitpierre F, Bernhard JC, Le Bras Y, et al. Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours. *Eur Radiol* 2014;24:1068-1080
 67. Lanzman RS, Robson PM, Sun MR, Patel AD, Mentore K, Wagner AA, et al. Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings. *Radiology* 2012;265:799-808
 68. Lassel EA, Rao R, Schwenke C, Schoenberg SO, Michaely HJ. Diffusion-weighted imaging of focal renal lesions: a meta-analysis. *Eur Radiol* 2014;24:241-249
 69. Choyke PL. Imaging of hereditary renal cancer. *Radiol Clin North Am* 2003;41:1037-1051
 70. Rowsell C, Fleshner N, Marrano P, Squire J, Evans A. Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. *J Clin Pathol* 2007;60:426-428
 71. Davis CJ Jr, Barton JH, Sesterhenn IA, Mostofi FK. Metanephric adenoma. Clinicopathological study of fifty patients. *Am J Surg Pathol* 1995;19:1101-1114
 72. Patankar T, Punekar S, Madiwale C, Prasad S, Hanchate V. Metanephric adenoma in a solitary kidney. *Br J Radiol* 1999;72:80-81
 73. Fielding JR, Visweswaran A, Silverman SG, Granter SR, Renshaw AA. CT and ultrasound features of metanephric adenoma in adults with pathologic correlation. *J Comput Assist Tomogr* 1999;23:441-444
 74. Araki T, Hata H, Asakawa E, Araki T. MRI of metanephric adenoma. *J Comput Assist Tomogr* 1998;22:87-90

75. Prasad SR, Surabhi VR, Menias CO, Raut AA, Chintapalli KN. Benign renal neoplasms in adults: cross-sectional imaging findings. *AJR Am J Roentgenol* 2008;190:158-164
76. Katabathina VS, Vikram R, Nagar AM, Tamboli P, Menias CO, Prasad SR. Mesenchymal neoplasms of the kidney in adults: imaging spectrum with radiologic-pathologic correlation. *Radiographics* 2010;30:1525-1540
77. Steiner M, Quinlan D, Goldman SM, Millmond S, Hallowell MJ, Stutzman RE, et al. Leiomyoma of the kidney: presentation of 4 new cases and the role of computerized tomography. *J Urol* 1990;143:994-998
78. Radvany MG, Shanley DJ, Gagliardi JA. Magnetic resonance imaging with computed tomography of a renal leiomyoma. *Abdom Imaging* 1994;19:67-69
79. Martin SA, Mynderse LA, Lager DJ, Cheville JC. Juxtaglomerular cell tumor: a clinicopathologic study of four cases and review of the literature. *Am J Clin Pathol* 2001;116:854-863
80. Conn JW, Cohen EL, Lucas CP, McDonald WJ, Mayor GH, Blough WM Jr, et al. Primary reninism. Hypertension, hyperreninemia, and secondary aldosteronism due to renin-producing juxtaglomerular cell tumors. *Arch Intern Med* 1972;130:682-696
81. Prasad SR, Narra VR, Shah R, Humphrey PA, Jagirdar J, Catena JR, et al. Segmental disorders of the nephron: histopathological and imaging perspective. *Br J Radiol* 2007;80:593-602
82. Dunnick NR, Hartman DS, Ford KK, Davis CJ Jr, Amis ES Jr. The radiology of juxtaglomerular tumors. *Radiology* 1983;147:321-326
83. Remzi M, Katzenbeisser D, Waldert M, Klingler HC, Susani M, Memarsadeghi M, et al. Renal tumour size measured radiologically before surgery is an unreliable variable for predicting histopathological features: benign tumours are not necessarily small. *BJU Int* 2007;99:1002-1006
84. Duchene DA, Lotan Y, Cadeddu JA, Sagalowsky AI, Koeneman KS. Histopathology of surgically managed renal tumors: analysis of a contemporary series. *Urology* 2003;62:827-830
85. Silver DA, Morash C, Brenner P, Campbell S, Russo P. Pathologic findings at the time of nephrectomy for renal mass. *Ann Surg Oncol* 1997;4:570-574
86. Herts BR, Baker ME. The current role of percutaneous biopsy in the evaluation of renal masses. *Semin Urol Oncol* 1995;13:254-261
87. Rybicki FJ, Shu KM, Cibas ES, Fielding JR, vanSonnenberg E, Silverman SG. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. *AJR Am J Roentgenol* 2003;180:1281-1287
88. Sahni VA, Silverman SG. Biopsy of renal masses: when and why. *Cancer Imaging* 2009;9:44-55
89. Helm CW, Burwood RJ, Harrison NW, Melcher DH. Aspiration cytology of solid renal tumours. *Br J Urol* 1983;55:249-253
90. Murphy WM, Zambroni BR, Emerson LD, Moinuddin S, Lee LH. Aspiration biopsy of the kidney. Simultaneous collection of cytologic and histologic specimens. *Cancer* 1985;56:200-205
91. Bonzanini M, Pea M, Martignoni G, Zamboni G, Capelli P, Bernardello F, et al. Preoperative diagnosis of renal angiomyolipoma: fine needle aspiration cytology and immunocytochemical characterization. *Pathology* 1994;26:170-175
92. Gupta RK, Nowitz M, Wakefield SJ. Fine-needle aspiration cytology of renal angiomyolipoma: report of a case with immunocytochemical and electron microscopic findings. *Diagn Cytopathol* 1998;18:297-300
93. Liu J, Fanning CV. Can renal oncocytomas be distinguished from renal cell carcinoma on fine-needle aspiration specimens? A study of conventional smears in conjunction with ancillary studies. *Cancer* 2001;93:390-397
94. Renshaw AA, Lee KR, Madge R, Granter SR. Accuracy of fine needle aspiration in distinguishing subtypes of renal cell carcinoma. *Acta Cytol* 1997;41:987-994
95. Zhou M, Roma A, Magi-Galluzzi C. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. *Clin Lab Med* 2005;25:247-257
96. Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Review. *Radiology* 1991;178:253-258
97. Silverman SG, Gan YU, Morteale KJ, Tuncali K, Cibas ES. Renal masses in the adult patient: the role of percutaneous biopsy. *Radiology* 2006;240:6-22
98. Wehle MJ, Grabstald H. Contraindications to needle aspiration of a solid renal mass: tumor dissemination by renal needle aspiration. *J Urol* 1986;136:446-448
99. Slywotzky C, Maya M. Needle tract seeding of transitional cell carcinoma following fine-needle aspiration of a renal mass. *Abdom Imaging* 1994;19:174-176